Profile data is unavailable for this security.
About the company
PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.
- Revenue in GBP (TTM)2.62m
- Net income in GBP-51.67m
- Incorporated2015
- Employees90.00
- LocationPureTech Health PLC6 Tide Street, Suite 400BOSTON 02210United StatesUSA
- Phone+1 (617) 482-2333
- Fax+1 (617) 482-3337
- Websitehttps://puretechhealth.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Faron Pharmaceuticals Oy | 0.00 | -26.35m | 141.23m | 34.00 | -- | -- | -- | -- | -0.404 | -0.404 | 0.00 | -0.1877 | 0.00 | -- | -- | 0.00 | -287.97 | -213.06 | -- | -963.12 | -- | -- | -- | -- | -- | -12.02 | -- | -- | -- | -- | -7.71 | -- | -16.05 | -- |
Animalcare Group Plc | 74.35m | 1.20m | 147.31m | 220.00 | 124.17 | 1.88 | 16.54 | 1.98 | 0.0197 | 0.0197 | 1.23 | 1.30 | 0.6608 | 2.63 | 5.54 | -- | 1.07 | 0.3272 | 1.30 | 0.3866 | 58.30 | 53.90 | 1.61 | 0.5484 | 1.05 | 6.34 | 0.0701 | 599.95 | 3.82 | 0.5138 | -38.98 | -- | -11.79 | 2.59 |
Avacta Group Plc | 16.03m | -42.08m | 157.98m | 120.00 | -- | 5.33 | -- | 9.86 | -0.1605 | -0.1633 | 0.0606 | 0.0826 | 0.2406 | 4.50 | 2.38 | 133,541.70 | -63.18 | -- | -119.23 | -- | 54.40 | -- | -262.60 | -- | 0.6603 | -1.66 | 0.6913 | -- | 228.22 | -- | -49.92 | -- | -- | -- |
Allergy Therapeutics plc | 53.26m | -50.22m | 162.06m | 635.00 | -- | 6.12 | -- | 3.04 | -0.0266 | -0.0266 | 0.017 | 0.0056 | 0.7571 | 2.21 | 4.92 | 83,870.87 | -71.39 | -11.59 | -102.10 | -15.15 | 52.54 | 70.08 | -94.29 | -11.78 | 0.9281 | -7.93 | 0.2713 | -- | -18.11 | -2.71 | -212.65 | -- | 16.41 | -- |
4Basebio PLC | 354.00k | -6.28m | 179.91m | -- | -- | 50.74 | -- | 508.23 | -0.5094 | -0.5094 | 0.0287 | 0.2769 | 0.0296 | 0.3977 | 4.88 | -- | -52.42 | -- | -60.21 | -- | 80.51 | -- | -1,772.60 | -- | 3.28 | -40.29 | 0.6683 | -- | -20.71 | -- | -59.20 | -- | -- | -- |
hVIVO PLC | 56.04m | 16.12m | 180.30m | 274.00 | 11.33 | 5.25 | 9.57 | 3.22 | 0.0234 | 0.0234 | 0.0817 | 0.0505 | 0.8327 | -- | 4.08 | 204,536.50 | 23.94 | -0.643 | 46.27 | -1.29 | -- | -- | 28.75 | -0.765 | 1.47 | -- | 0.2674 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
Alliance Pharma plc | 170.05m | -7.06m | 208.59m | 249.00 | -- | 0.7528 | 66.60 | 1.23 | -0.0131 | -0.0131 | 0.3145 | 0.5127 | 0.3202 | 2.88 | 4.40 | 682,927.70 | -1.33 | 2.64 | -1.47 | 2.95 | 57.58 | 63.38 | -4.15 | 8.35 | 1.38 | 2.18 | 0.31 | 53.41 | 2.58 | 10.50 | -87.21 | -49.62 | -25.78 | 5.94 |
Bioventix PLC | 13.60m | 8.67m | 227.06m | 16.00 | 26.65 | 19.86 | 25.84 | 16.70 | 1.63 | 1.63 | 2.56 | 2.19 | 1.09 | 1.53 | 2.54 | 849,780.60 | 69.72 | 56.43 | 79.03 | 61.01 | 93.75 | 92.64 | 63.73 | 65.08 | 6.69 | -- | 0.00 | 84.49 | 9.36 | 7.93 | 9.10 | 8.13 | -37.12 | 20.03 |
Niox Group PLC | 36.80m | 9.50m | 302.77m | 85.00 | 33.77 | 3.34 | 21.78 | 8.23 | 0.0211 | 0.0238 | 0.0819 | 0.2136 | 0.3874 | 2.31 | 6.13 | 432,941.20 | 10.00 | -2.41 | 10.57 | -2.90 | 72.01 | 70.87 | 25.82 | -11.46 | 3.99 | -- | 0.013 | -- | 17.57 | -5.29 | -32.62 | -- | -5.59 | -- |
Oxford BioMedica plc | 89.54m | -157.49m | 334.50m | 714.00 | -- | 4.38 | -- | 3.74 | -1.63 | -1.63 | 0.9273 | 0.7645 | 0.2513 | 3.91 | 3.07 | 125,404.80 | -51.69 | -19.60 | -64.26 | -24.68 | 44.37 | 50.74 | -205.68 | -44.38 | 2.90 | -22.92 | 0.5888 | -- | -36.04 | 6.04 | -302.20 | -- | -0.6307 | -- |
Puretech Health PLC | 2.62m | -51.74m | 610.65m | 90.00 | -- | 1.68 | -- | 232.83 | -0.1857 | -0.1857 | 0.0094 | 1.34 | 0.0048 | -- | 0.4676 | 29,140.83 | -9.54 | 4.92 | -10.67 | 5.94 | -- | -- | -2,000.84 | 352.67 | -- | -- | 0.0524 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
Genus plc | 673.10m | 33.40m | 1.21bn | 3.48k | 36.21 | 2.10 | 15.67 | 1.80 | 0.5053 | 0.5053 | 10.18 | 8.71 | 0.6478 | -- | 6.03 | 193,642.10 | 2.90 | 3.58 | 3.30 | 4.20 | -- | -- | 4.47 | 5.44 | 1.40 | 5.44 | 0.3377 | 60.86 | 16.23 | 7.96 | -18.58 | 26.70 | 9.36 | 4.24 |
Indivior PLC | 885.25m | 3.94m | 1.80bn | 1.05k | 407.37 | 229.46 | 71.24 | 2.03 | -0.0163 | -0.0163 | 6.16 | 0.058 | 0.7008 | 1.35 | 4.87 | 842,294.20 | 0.3117 | 1.32 | 0.7669 | 2.62 | 82.83 | 83.69 | 0.4448 | 2.68 | 0.7352 | -- | 0.9654 | 0.00 | 21.31 | 1.69 | 96.00 | -- | 5.27 | -- |
Holder | Shares | % Held |
---|---|---|
Invesco Asset Management Ltd.as of 31 Mar 2023 | 64.95m | 24.04% |
Lansdowne Partners (UK) LLPas of 31 Mar 2023 | 24.37m | 9.02% |
Baillie Gifford & Co.as of 31 Mar 2023 | 22.52m | 8.34% |
Jupiter Asset Management Ltd.as of 15 Jul 2020 | 14.25m | 5.27% |
M&G Investment Management Ltd.as of 31 Mar 2023 | 11.76m | 4.35% |
Miller Value Partners LLCas of 31 Mar 2021 | 10.04m | 3.71% |
Patient Capital Management, Inc.as of 31 Mar 2023 | 9.81m | 3.63% |
Eurizon Capital SGR SpAas of 02 Apr 2024 | 9.56m | 3.54% |
The Vanguard Group, Inc.as of 02 Apr 2024 | 6.60m | 2.44% |
Canaccord Genuity Asset Management Ltd.as of 07 Oct 2022 | 5.34m | 1.98% |